ArticleNucleic acids research2017
Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases.
Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Cas10 residues lining the target RNA binding channel regulate interference by distinguishing cognate target RNA from mismatched targets.RNA biology · 2026Article
- Structural insights into RNA recognition by theProceedings of the National Academy of Sciences of the United States of America · 2026Article
- TIGR-Tas and the Expanding Universe of RNA-Guided Genome Editing Systems: A New Era Beyond CRISPR-Cas.Genes · 2025Review
- Structural and molecular mechanisms of an Ro60 homolog from a Thermus bacteriophage.Nucleic acids research · 2025Article
- Article
- AcrIIIA1 is a protein-RNA anti-CRISPR complex that targets core Cas and accessory nucleases.Nucleic acids research · 2024Article
- RNA processing by the CRISPR-associated NYN ribonuclease.The Biochemical journal · 2024Article
- Type III CRISPR-Cas: beyond the Cas10 effector complex.Trends in biochemical sciences · 2024Review
- Genetic Engineering of Therapeutic Phages Using Type III CRISPR-Cas Systems.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The phage fought the cells, and the phage won: a satellite symposium at the ASV 2023 annual meeting.Journal of virology · 2023Article
- Article
- Article
- CRISPR-Cas9 Based Bacteriophage Genome Editing.Microbiology spectrum · 2022Article
- Structures of an active type III-A CRISPR effector complex.Structure (London, England : 1993) · 2022Article
- SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation.Nature communications · 2021Article
- Structural and biochemical characteristics of twoThe Journal of biological chemistry · 2020Article
- Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.The Journal of biological chemistry · 2020Review
- A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.RNA biology · 2019Article
- Regulation of cyclic oligoadenylate synthesis by theRNA (New York, N.Y.) · 2019Article
- Target sequence requirements of a type III-B CRISPR-Cas immune system.The Journal of biological chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
CRISPR–Cas (Clustered regularly interspaced short palindromic repeats-CRISPR-associated proteins) is a prokaryotic immune system that destroys foreign nucleic acids in a sequence-specific manner using Cas nucleases guided by short RNAs (crRNAs). Staphylococcus epidermidis harbours a Type III-A CRISPR–Cas system that encodes the Cas10–Csm interference complex and crRNAs that are subjected to multiple processing steps. The final step, called maturation, involves a concerted effort between Csm3, a ruler protein in Cas10–Csm that measures six-nucleotide increments, and the activity of a nuclease(s) that remains unknown. Here, we elucidate the contributions of the Cas10–Csm complex toward maturation and explore roles of non-Cas nucleases in this process. Using genetic and biochemical approaches, we show that charged residues in Csm3 facilitate its self-assembly and dictate the extent of maturation cleavage. Additionally, acidic residues in Csm5 are required for efficient maturation, but recombinant Csm5 fails to cleave crRNAs in vitro. However, we detected cellular nucleases that co-purify with Cas10–Csm, and show that Csm5 regulates their activities through distinct mechanisms. Altogether, our results support roles for non-Cas nuclease(s) during crRNA maturation and establish a link between Type III-A CRISPR–Cas immunity and central nucleic acid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.